Behzadnia Neda, Sharif Kashani Babak, Kiani Arda, Abedini Atefe, Seyedi Seyed Reza, Zargham Ahmadi Hossein, Naghash Zadeh Farah, Fakharian Atefeh
Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Chronic Respiratory Diseases Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Tanaffos. 2016;15(2):117-120.
Thrombosis is a life threatening complications of prosthetic mitral valves and is associated with high morbidity and mortality. Even in presence of systemic anticoagulation prosthetic valve thrombosis has an incidence of 0.5% to 8%. Recurrent prosthetic valve thrombosis and the resulting thrombotic occlusion require re-establishment of blood flow across the valve. While surgical repair is considered the classic first line treatment option for prosthetic valve thrombosis, intravenous thrombolysis has emerged as an acceptable alternative for the first episode of prosthetic valve thrombosis. Due to the limitation of using streptokinase in recurrent thrombotic events, fibrin-specific tissue plasminogen activators have been successfully utilized to treat cases of recurrent prosthetic valve thrombosis. In this case-series, we have reported four cases of recurrent prosthetic valve thrombosis that were successfully treated with Reteplase at our hospital.
血栓形成是人工二尖瓣危及生命的并发症，与高发病率和死亡率相关。即使在进行全身抗凝治疗的情况下，人工瓣膜血栓形成的发生率仍为0.5%至8%。复发性人工瓣膜血栓形成及由此导致的血栓性阻塞需要重新建立瓣膜的血流。虽然手术修复被认为是人工瓣膜血栓形成的经典一线治疗选择，但静脉溶栓已成为人工瓣膜血栓形成首发事件的可接受替代方案。由于链激酶在复发性血栓事件中的使用受限，纤维蛋白特异性组织纤溶酶原激活剂已成功用于治疗复发性人工瓣膜血栓形成病例。在本病例系列中，我们报告了我院4例用瑞替普酶成功治疗的复发性人工瓣膜血栓形成病例。
